Results of hepatitis C treatment with Sofosbuvir and Daclatasvir among people living with HIV on antiretroviral therapy in Thai Nguyen province in 2022
DOI:
https://doi.org/10.51403/0868-2836/2022/898Keywords:
Co-infection HCV/HIV, Hepatitis C, Sofosbuvir and DaclatasvirAbstract
A cross - sectional study was conducted to describe the outcome of hepatitis C treatment and its associated factors among HIV and hepatitis C co-infected people on ART in Thai Nguyen in 2022. The data were collected from the electronic medical records of 350 patients who had completed hepatitis C treatment and had the results of hepatitis C viral load. The findings showed that 86.0% of participants
had a history of diagnosis with viral hepatitis, 8.9% had compensated cirrhosis, and 2.9% tested positive for HBsAg. The HIV virus load in the last 12 months of < 200cp/ml accounted for 92.9%. After 12 weeks of treatment with Sofosbuvir and Daclatasvir regimens, the success rate of HCV treatment among participants reached 96.6%.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Publication License No 150/GP-BTTTT signed on May 8, 2014;
Electronic Publication License No 322/GP-BTTTT signed on June 15, 2016.